Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
How would you manage a newly diagnosed AML in a patient with concurrent metastatic castrate-resistant prostate cancer that has progressed on enzalutamide with a doubling time of two months?
Related Questions
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
How should one approach an incidentally found T-cell gene arrangement?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
For AML patients, when do you stop antiinfective agents?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
